This trial is investigating the side effects and efficacy of CD19 CAR T cells and acalabrutinib in treating patients with mantle cell lymphoma.
2 Primary · 6 Secondary · Reporting Duration: Up to 15 year post CAR T cell infusion
Experimental Treatment
36 Total Participants · 1 Treatment Group
Primary Treatment: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes · No Placebo Group · Phase 2
Age 18 - 75 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: